NCT07275073

JMT106 Injection in the Treatment of Advanced Solid Tumors

A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, Immunogenicity, and Preliminary Antitumor Activity of JMT106 Injection in Patients With Advanced Solid Tumors

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: Shanghai JMT-Bio Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is the first-in-human Phase I study of JMT106 injection, comprising two phases: Dose escalation with backfill and cohort expansion. The planned study population consists of subjects with advanced solid tumors. The objective is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of JMT106 injection as monotherapy in participants with advanced solid tumors

Conditions

• Advanced Solid Tumor
• Lung Squamous Cell Carcinoma
• Hepatocellular Carcinoma

Interventions

Type	Name	Description
DRUG	JMT106 Injection	Use according to the protocol.

Timeline

• Start date: 2025-09-25
• Primary completion: 2026-11-05
• Completion: 2028-11-15
• First posted: 2025-12-10
• Last updated: 2025-12-18

Locations

1 site across 1 country: China

Regulatory

• FDA-regulated drug study